search
Back to results

Pilot Study of a Novel IPL for Removal of Unwanted Fine Body Hair

Primary Purpose

Hypertrichosis

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Prowave LX IPL
Sponsored by
Cutera Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertrichosis focused on measuring intense pulsed light, IPL, healthy volunteer, light-based hair removal, hair removal, epilation, laser hair removal, permanent hair reduction

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Female or Male, 18 to 65 years of age (inclusive).
  • Fitzpatrick Skin Type I - III.
  • Subject has black or dark brown unwanted arm hair of fine texture.
  • Willing to have the hair removal procedure on one forearm only, and within the designated study treatment area.
  • Willing and able to adhere to the treatment and follow-up schedule, and the study "Before and After Procedure Instructions".
  • Willing to refrain from shaving the treatment area for 5 days prior to each study visit.
  • Must be able to read, understand and sign the Informed Consent Form.
  • Must agree not to use hair removal products, such as topical chemical depilatories, or undergo any other hair removal procedure during the study, such as other laser and light therapies or waxing.
  • Willing to refrain from excess sun exposure and willing to wear sunscreen on the treatment area during the study (including the follow-up period).
  • Willing to have digital photographs taken of the treatment area and agree to use of photographs for presentation, educational or marketing purposes.
  • Must be in good health, as determined by the Investigator.
  • Must be post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study.

Exclusion Criteria:

  • Participation in a clinical trial of another device or drug within 6 months prior to enrollment, or during the study.
  • Had any type of professional hair removal procedure, such as laser, light-based, RF or electrolysis, in the treatment area within 12 months of study participation.
  • Had other epilation treatment, such as waxing or mechanical epilator, in the treatment area within 6 months of study participation.
  • Subject shows signs of actinic bronzing or recent tanning in the treatment area, and unable/unlikely to refrain from tanning during the study.
  • Subject is pregnant and/or breastfeeding.
  • Suffering from significant concurrent illness, such as diabetes mellitus or pertinent neurological disorders.
  • Having malignant or pre-malignant lesions in the treatment area, or history of a malignant skin disease.
  • Current acute or chronic skin infections or inflammatory processes, affecting the treatment area, such as dermatitis.
  • Currently using immunosuppressive medications or history of immunosuppression/immune deficiency disorder, such as psoriasis, eczema, vitiligo, systemic lupus erythematosus or scleroderma.
  • Current use of any medication that is known to increase sensitivity to light, such as tetracycline.
  • Currently undergoing systemic chemotherapy or radiation treatment for cancer, or history of treatment within 3 months of study participation.
  • Suffering from coagulation disorders or taking prescription anticoagulation medications.
  • History of keloid formation, hypertrophic scarring or abnormal/delayed wound healing.
  • History of seizure disorders due to light.
  • History of diseases stimulated by heat, such as recurrent herpes zoster in the treatment area, unless treatment is conducted following a prophylactic regimen.
  • History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation.
  • History of tattoo, permanent make-up or semi-permanent or permanent tissue fillers in the treatment area.
  • Systemic use of a retinoid (such as Accutane) or corticosteroid within 6 months of study participation.
  • Current smoker or history of smoking within 12 months of study participation.
  • Anytime in life, had used gold therapy (gold salts) for disorders such as rheumatologic disease or lupus.
  • As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.

Sites / Locations

  • Sadick Research Group

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Prowave LX IPL

No Treatment

Arm Description

One area on forearm will receive treatment with Prowave LX IPL

No treatment administered on one area of forearm

Outcomes

Primary Outcome Measures

Comparison of Percent Hair Reduction Between Treatment Arm and Non-treated Control Arm at 12 Weeks Post Final Treatment

Secondary Outcome Measures

Full Information

First Posted
July 18, 2013
Last Updated
January 26, 2023
Sponsor
Cutera Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01912950
Brief Title
Pilot Study of a Novel IPL for Removal of Unwanted Fine Body Hair
Official Title
Randomized, Controlled, Open-Label Pilot Study of a Novel IPL for Removal of Unwanted Fine Hair
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Completed
Study Start Date
December 2013 (undefined)
Primary Completion Date
July 2015 (Actual)
Study Completion Date
July 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cutera Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this randomized, controlled, open-label pilot study is to evaluate the safety and efficacy of a novel intense pulsed light (IPL) device for removal of unwanted fine body hair. Subjects will have IPL treatment on one forearm area. Another area will serve as the un-treated control area. Subjects will be followed at 12-weeks post-final treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertrichosis
Keywords
intense pulsed light, IPL, healthy volunteer, light-based hair removal, hair removal, epilation, laser hair removal, permanent hair reduction

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
11 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Prowave LX IPL
Arm Type
Experimental
Arm Description
One area on forearm will receive treatment with Prowave LX IPL
Arm Title
No Treatment
Arm Type
No Intervention
Arm Description
No treatment administered on one area of forearm
Intervention Type
Device
Intervention Name(s)
Prowave LX IPL
Other Intervention Name(s)
Prowave, Prowave LX, Cutera Prowave LX, Intense Pulsed Light, IPL, Flashlamp Infared device, Hair removal
Primary Outcome Measure Information:
Title
Comparison of Percent Hair Reduction Between Treatment Arm and Non-treated Control Arm at 12 Weeks Post Final Treatment
Time Frame
12-weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Female or Male, 18 to 65 years of age (inclusive). Fitzpatrick Skin Type I - III. Subject has black or dark brown unwanted arm hair of fine texture. Willing to have the hair removal procedure on one forearm only, and within the designated study treatment area. Willing and able to adhere to the treatment and follow-up schedule, and the study "Before and After Procedure Instructions". Willing to refrain from shaving the treatment area for 5 days prior to each study visit. Must be able to read, understand and sign the Informed Consent Form. Must agree not to use hair removal products, such as topical chemical depilatories, or undergo any other hair removal procedure during the study, such as other laser and light therapies or waxing. Willing to refrain from excess sun exposure and willing to wear sunscreen on the treatment area during the study (including the follow-up period). Willing to have digital photographs taken of the treatment area and agree to use of photographs for presentation, educational or marketing purposes. Must be in good health, as determined by the Investigator. Must be post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study. Exclusion Criteria: Participation in a clinical trial of another device or drug within 6 months prior to enrollment, or during the study. Had any type of professional hair removal procedure, such as laser, light-based, RF or electrolysis, in the treatment area within 12 months of study participation. Had other epilation treatment, such as waxing or mechanical epilator, in the treatment area within 6 months of study participation. Subject shows signs of actinic bronzing or recent tanning in the treatment area, and unable/unlikely to refrain from tanning during the study. Subject is pregnant and/or breastfeeding. Suffering from significant concurrent illness, such as diabetes mellitus or pertinent neurological disorders. Having malignant or pre-malignant lesions in the treatment area, or history of a malignant skin disease. Current acute or chronic skin infections or inflammatory processes, affecting the treatment area, such as dermatitis. Currently using immunosuppressive medications or history of immunosuppression/immune deficiency disorder, such as psoriasis, eczema, vitiligo, systemic lupus erythematosus or scleroderma. Current use of any medication that is known to increase sensitivity to light, such as tetracycline. Currently undergoing systemic chemotherapy or radiation treatment for cancer, or history of treatment within 3 months of study participation. Suffering from coagulation disorders or taking prescription anticoagulation medications. History of keloid formation, hypertrophic scarring or abnormal/delayed wound healing. History of seizure disorders due to light. History of diseases stimulated by heat, such as recurrent herpes zoster in the treatment area, unless treatment is conducted following a prophylactic regimen. History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation. History of tattoo, permanent make-up or semi-permanent or permanent tissue fillers in the treatment area. Systemic use of a retinoid (such as Accutane) or corticosteroid within 6 months of study participation. Current smoker or history of smoking within 12 months of study participation. Anytime in life, had used gold therapy (gold salts) for disorders such as rheumatologic disease or lupus. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Neil Sadick
Organizational Affiliation
Study Principal Investigator
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sadick Research Group
City
New York
State/Province
New York
ZIP/Postal Code
10075
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Pilot Study of a Novel IPL for Removal of Unwanted Fine Body Hair

We'll reach out to this number within 24 hrs